This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ebselen
Accession Number
DB12610
Description

Ebselen has been investigated for the treatment and basic science of Meniere's Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 274.192
Monoisotopic: 274.984936
Chemical Formula
C13H9NOSe
Synonyms
  • Ebselen
  • ebseleno
External IDs
  • DR-3305
  • DR3305
  • SPI-1005

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UBifunctional epoxide hydrolase 2
inhibitor
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Abciximab.
AcebutololEbselen may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Ebselen.
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Ebselen.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Acenocoumarol.
AcetaminophenThe risk or severity of adverse effects can be increased when Acetaminophen is combined with Ebselen.
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Ebselen.
Acetylsalicylic acidThe risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Acetylsalicylic acid.
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Ebselen.
Alendronic acidThe risk or severity of adverse effects can be increased when Ebselen is combined with Alendronic acid.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Selenazoles / Heteroaromatic compounds / Lactams / Azacyclic compounds / Organoselenium compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
1,2-selenazole / Aromatic heteropolycyclic compound / Azacycle / Heteroaromatic compound / Hydrocarbon derivative / Lactam / Monocyclic benzene moiety / Organic nitrogen compound / Organic oxide / Organic oxygen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
benzoselenazole (CHEBI:77543)

Chemical Identifiers

UNII
40X2P7DPGH
CAS number
60940-34-3
InChI Key
DYEFUKCXAQOFHX-UHFFFAOYSA-N
InChI
InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H
IUPAC Name
2-phenyl-2,3-dihydro-1,2-benzoselenazol-3-one
SMILES
O=C1N([Se]C2=CC=CC=C12)C1=CC=CC=C1

References

General References
Not Available
PubChem Compound
3194
PubChem Substance
347828824
ChemSpider
3082
BindingDB
34233
ChEBI
77543
ChEMBL
CHEMBL51085
Wikipedia
Ebselen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionTemporary Auditory Threshold Shift1
2CompletedTreatmentBipolar Disorder (BD) / Bipolar Disorder, Manic1
2CompletedTreatmentMenière's Disease1
2Enrolling by InvitationTreatmentOtotoxicity1
2Not Yet RecruitingTreatmentHead and Neck Carcinoma / Hearing loss or impairment / Lung Cancers / Neuropathies / Ototoxicity / Tinnitus1
2Not Yet RecruitingTreatmentHearing Loss, Noise-Induced1
2Not Yet RecruitingTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)2
2, 3CompletedBasic ScienceType 1 Diabetes Mellitus / Type 2 Diabetes Mellitus1
1CompletedTreatmentHearing loss or impairment / Malignancies1
1, 2CompletedTreatmentMenière's Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility4.35 mg/mLALOGPS
logP1.91ALOGPS
logP2.65ChemAxon
logS-1.8ALOGPS
pKa (Strongest Basic)-5.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity71.54 m3·mol-1ChemAxon
Polarizability23.06 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
irreversible inhibitor of soluble epoxide hydrolase (sEH)
General Function
Toxic substance binding
Specific Function
Bifunctional enzyme. The C-terminal domain has epoxide hydrolase activity and acts on epoxides (alkene oxides, oxiranes) and arene oxides. Plays a role in xenobiotic metabolism by degrading potenti...
Gene Name
EPHX2
Uniprot ID
P34913
Uniprot Name
Bifunctional epoxide hydrolase 2
Molecular Weight
62615.22 Da
References
  1. Morisseau C, Sahdeo S, Cortopassi G, Hammock BD: Development of an HTS assay for EPHX2 phosphatase activity and screening of nontargeted libraries. Anal Biochem. 2013 Mar 1;434(1):105-11. doi: 10.1016/j.ab.2012.11.017. Epub 2012 Dec 3. [PubMed:23219563]

Drug created on October 20, 2016 17:12 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates